Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

FOLFIRI-cetuximab regimen

View Patient Information
A chemoimmunotherapy regimen consisting of leucovorin (folinic acid), 5-fluorouracil, and irinotecan plus cetuximab used for the treatment of metastatic colorectal cancer that is positive for the expression of the epidermal growth factor receptor (EGFR) and the wild-type form of KRAS.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:FOLFIRI-Erbitux regimen
leucovorin-fluorouracil-irinotecan-cetuximab regimen
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search